The White House scrapped plans to hold a meeting today at a Baltimore-based vaccine plant run by Emergent BioSolutions following an exposé from The New York Times. The Biden administration also announced plans to conduct an audit of the Strategic National Stockpile after the publication of the article, which described how the biopharmaceutical company lobbied…
J&J to pay Emergent BioSolutions an initial $480m to make COVID-19 vaccine
Emergent BioSolutions announced a five-year manufacturing agreement with Johnson & Johnson’s (NYSE:JNJ) Janssen Pharmaceuticals for the parent company’s SARS-CoV-2 vaccine candidate. Gaithersburg, Md.-based Emergent is set to provide contract development and manufacturing services to produce Johnson & Johnson’s Ad26.COV2-S vaccine candidate at scale over five years, with the deal valued at approximately $480 million for…
How Johnson & Johnson is expanding manufacturing for a potential coronavirus vaccine
Johnson & Johnson (NYSE:JNJ) recently announced that its Janssen Pharmaceutical Cos. will collaborate with Emergent BioSolutions to support the manufacturing of its lead investigational COVID-19 vaccine candidate. The New Brunswick, N.J.–based pharmaceutical and medical device giant described the deal as the first in a series of contract manufacturing agreements that it expects to ink as…